Monitor Orthopaedic Footwear Questionnaire (MOS) Validity and Reliability Study
Launched by MEDIPOL UNIVERSITY · Jun 13, 2025
Trial Information
Current as of November 08, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is about translating the Monitor Orthopaedic Shoes Questionnaire (MOS) into Turkish (called MOS-T) and testing whether the Turkish version is both valid (it measures what it’s supposed to) and reliable (it produces consistent results). It’s an observational study, meaning researchers will observe and collect survey data rather than test a treatment. About 200 people who use orthopedic shoes are being invited to participate. Eligible participants are aged 16 to 75, native Turkish speakers who can read and fill out the survey, are wearing orthopedic shoes for the first time, and can complete the questionnaire without help. The work is taking place at Istanbul Medipol University in Istanbul.
If you join, you’ll complete the MOS-T questionnaire once, and then redo it about 8 weeks later to see if responses stay stable over time. The researchers will use standard statistics to check that MOS-T matches the original questionnaire and works consistently. This study is overseen by a monitoring committee and is not a drug or device trial. Enrollment is ongoing by invitation, with start around June 30, 2025 and an estimated finish around November 30, 2025. Results will be shared later, but individual results are not yet available.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Wearing orthopedic shoes for the first time,
- • Being 16 years old and above,
- • Being a native Turkish speaker and having at least a literacy level,
- • Being able to complete the survey without assistance regarding cognitive or physical disorders,
- • Volunteering to participate in the study
About Medipol University
Medipol University is a leading academic institution dedicated to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices. Leveraging state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Medipol University is committed to contributing to the global medical community through ethical research and the development of novel therapeutic strategies. The institution fosters an environment of academic excellence and integrity, ensuring that all trials adhere to the highest standards of safety and efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beykoz, Istanbul, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported